HK Stock MarketDetailed Quotes

02257 SIRNAOMICS-B

Watchlist
  • 2.920
  • +0.100+3.55%
Market Closed Dec 11 16:08 CST
307.09MMarket Cap-480P/E (TTM)

About SIRNAOMICS-B Company

siRNAomics is the first and only clinical-stage RNA therapy biopharmaceutical company with significant market positions in both China and the US. It explores and develops innovative drugs for human diseases with significant unmet medical needs. The clinical development pipeline focuses on oncology and fibrosis indications. Our management team shares extensive experience and ability to explore, develop, and commercialize RNAi therapies. Our mission is to become a fully integrated international biopharmaceutical company, drawing on our deep experience in RNA therapy and novel delivery platform technology to rapidly discover, develop, and (if approved) commercialize a range of transformative therapies and vaccines for patients with various rare and hugely marketable diseases.

Company Profile

Symbol02257
Company NameSIRNAOMICS-B
ISINKYG2050P1028
Listing DateDec 30, 2021
Issue Price65.90
Shares Offered7.54M share(s)
FoundedOct 15, 2020
Registered AddressCayman Islands
Chairmanyang lu
Secretaryrunting yuan
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business46th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees90
MarketHong Kong motherboard
Phone(852)31809494
Emailinfo-hk@sirnaomics.com
Websitehttp://www.sirnaomics.com
Business Sirnaomics Ltd is an investment holding company. The company and its subsidiaries are clinical-stage biotechnology companies engaged in the development and commercialization of ribonucleic acid interference (RNAi) technology and various therapies. The company is dedicated to the discovery and development of medicines for indications that do not meet medical needs in the region. Its main clinical candidates include STP705 and STP707. Its STP705 is a sterile pharmaceutical product used to treat non-melanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), keloids that recur after keloid resection, hypertrophic scars (HTS), and solid liver tumors, and in medical aesthetics. Its STP707 is a sterile pharmaceutical product used to treat solid tumors, including liver cancer, metastatic cutaneous squamous cell skin cancer (CSCC), and non-small cell lung cancer. It is utilizing its dual delivery platform, which includes polypeptide nanoparticles (PNP) and GalaHead.

Company Executives

  • Name
  • Position
  • Salary
  • yang lu
  • Chairman of the Board, President, Non-executive Directors, Chief Scientific Officer of the Group, Nomination Committee Members, Authorized Representative
  • --
  • honghui pan
  • CEOs, Executive Director
  • --
  • David Mark Evans
  • Head of Drug Development and Collaboration
  • --
  • jiankang zhang
  • Non-executive Directors, Remuneration Committee Members
  • --
  • changhai yu
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
  • --
  • runting yuan
  • Authorized Representative, Company Secretary
  • --
  • mengying huang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members
  • --
  • yun zhang
  • Chief Financial Officer in China, Board Secretary
  • --
  • yongji ye
  • Vice President of Corporate Finance
  • --
  • yongxiang wang
  • Chief Manufacturing Officer
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday+4.95%